Sigma Mostafa

R&D

Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.

News

ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.